Recombinant Map19-mediated inhibition of DTH. DbpA-immunized mice were treated with recombinant Map19 on the day of immunization (day 0) and on days 2, 4, and 6 after immunization. On day 7, mice were challenged with DbpA and footpads were measured 0 and 24 hours after challenge. Mice treated with recombinant Map19 had a significantly reduced DTH response compared with immunized and challenged mice (*P < 0.0001; Student t test). Data are expressed as the mean ± SE of five mice.